HRP920488A2 - Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism - Google Patents
Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism Download PDFInfo
- Publication number
- HRP920488A2 HRP920488A2 HR920488A HRP920488A HRP920488A2 HR P920488 A2 HRP920488 A2 HR P920488A2 HR 920488 A HR920488 A HR 920488A HR P920488 A HRP920488 A HR P920488A HR P920488 A2 HRP920488 A2 HR P920488A2
- Authority
- HR
- Croatia
- Prior art keywords
- pgm
- organism
- immunosuppressive
- carboxylic acid
- acyl derivatives
- Prior art date
Links
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 26
- 229910052751 metal Inorganic materials 0.000 title claims description 16
- 239000002184 metal Substances 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 7
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 title claims description 5
- 108010013639 Peptidoglycan Proteins 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title claims description 5
- 239000000178 monomer Substances 0.000 title claims description 5
- 238000012937 correction Methods 0.000 title description 10
- 206010002091 Anaesthesia Diseases 0.000 claims description 26
- 230000037005 anaesthesia Effects 0.000 claims description 26
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 20
- 229960003132 halothane Drugs 0.000 claims description 20
- 206010062016 Immunosuppression Diseases 0.000 claims description 17
- 206010040047 Sepsis Diseases 0.000 claims description 13
- 229940035674 anesthetics Drugs 0.000 claims description 9
- 239000003193 general anesthetic agent Substances 0.000 claims description 9
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 150000002739 metals Chemical class 0.000 claims description 8
- -1 alkyl carboxylic acid Chemical class 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010053615 Thermal burn Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 208000016253 exhaustion Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 208000014674 injury Diseases 0.000 description 11
- 230000008733 trauma Effects 0.000 description 11
- 230000035939 shock Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002350 laparotomy Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008775 paternal effect Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 230000001553 hepatotropic effect Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000000403 immunocorrecting effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 238000013296 A/J mouse Methods 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR920488A HRP920488A2 (en) | 1991-08-15 | 1992-09-25 | Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| YU141291 | 1991-08-15 | ||
| HR920488A HRP920488A2 (en) | 1991-08-15 | 1992-09-25 | Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP920488A2 true HRP920488A2 (en) | 1994-08-31 |
Family
ID=25554075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR920488A HRP920488A2 (en) | 1991-08-15 | 1992-09-25 | Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0600974A1 (fr) |
| JP (1) | JPH08506796A (fr) |
| BG (1) | BG98628A (fr) |
| CA (1) | CA2115270A1 (fr) |
| CZ (1) | CZ30194A3 (fr) |
| HR (1) | HRP920488A2 (fr) |
| HU (1) | HU9400420D0 (fr) |
| RU (1) | RU94027699A (fr) |
| SK (1) | SK17994A3 (fr) |
| WO (1) | WO1993003746A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU45382B (en) * | 1986-11-19 | 1992-05-28 | Pliva Sour Zagreb | Process for preparing complex of n-acethyl-glucosis-aminyl-n-acethyl-muramoil-l-alanyl-d-izoglutaminyl-(l)-mezodiaminopimelyl-(d-amid)-(l)-al |
| US4868155A (en) * | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts |
| YU62689A (en) * | 1989-03-27 | 1991-02-28 | Pliva Pharm & Chem Works | N-acyl derivatives of peptidoglican monomer, their pharmaceutically acceptable salts, process for preparing thereof and their use as immunity modulators and immunoadjuvant |
-
1992
- 1992-08-13 EP EP92917699A patent/EP0600974A1/fr not_active Withdrawn
- 1992-08-13 RU RU94027699/14A patent/RU94027699A/ru unknown
- 1992-08-13 JP JP5504098A patent/JPH08506796A/ja active Pending
- 1992-08-13 HU HU9400420A patent/HU9400420D0/hu unknown
- 1992-08-13 CZ CS94301A patent/CZ30194A3/cs unknown
- 1992-08-13 SK SK179-94A patent/SK17994A3/sk unknown
- 1992-08-13 CA CA002115270A patent/CA2115270A1/fr not_active Abandoned
- 1992-08-13 WO PCT/EP1992/001859 patent/WO1993003746A1/fr not_active Application Discontinuation
- 1992-09-25 HR HR920488A patent/HRP920488A2/hr not_active Application Discontinuation
-
1994
- 1994-03-01 BG BG98628A patent/BG98628A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2115270A1 (fr) | 1993-03-04 |
| EP0600974A1 (fr) | 1994-06-15 |
| BG98628A (en) | 1995-06-30 |
| WO1993003746A1 (fr) | 1993-03-04 |
| JPH08506796A (ja) | 1996-07-23 |
| CZ30194A3 (en) | 1994-06-15 |
| SK17994A3 (en) | 1994-08-10 |
| HU9400420D0 (en) | 1994-08-29 |
| RU94027699A (ru) | 1996-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gross et al. | 3: 5: 3′-Triiodothyronine. 2. Physiological activity | |
| PAYNE | Studies on the fat-mobilizing factor of the anterior pituitary gland | |
| Jefferson et al. | A direct effect of growth hormone on the incorporation of precursors into proteins and nucleic acids of perfused rat liver | |
| Li et al. | Effect of glutamine-enriched total parenteral nutrition on small intestinal gut-associated lymphoid tissue and upper respiratory tract immunity | |
| JPH05504341A (ja) | 吸入投与形態をとる自己免疫疾患および／または予防用薬剤 | |
| JPS6226218A (ja) | がん性腫瘍転移の治療剤 | |
| WO1997027870A1 (fr) | Medicaments prevenant ou guerissant la thrombopenie | |
| NO170114B (no) | Elektrisk kontaktklemme | |
| Nosáľvá et al. | Antitussive activity of a rhamnogalacturonan isolated from the roots of Althaea officinalis L., var. Robusta | |
| Mikos et al. | Effects of gastrin and its analogues on isolated smooth muscles | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| ROSS et al. | Changes in Tissue Concentrations of Thyrotropin, Free Thyrotropinβ, and α-Subunits after Thyroxine Administration: Comparison of Mouse Hypothyroid Pituitary and Thyrotropic Tumors | |
| BROWN et al. | Thyroid growth immunoglobulins in feline hyperthyroidism | |
| Gilbert | The effect of oestrogen and thyroxine on the blood volume of the domestic cock | |
| HRP920488A2 (en) | Application of peptidoglycan monomers (pgm) its n-acyl derivatives and metal complexes for the preparation of the medicine for the correction of immunosuppressive and hematosuppressive condition of an organism | |
| Purvis et al. | LH contamination may explain FSH effects on rat Leydig cells | |
| US5073555A (en) | Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels | |
| Scudi et al. | Some Pharmacological Characteristics of Bacitracin II. Absorption and Excretion of Bacitracin in the Dog. | |
| GB2078516A (en) | Pharmaceutical compositions containing arginine and lysine | |
| Stanley et al. | Cobalt polycythemia. II. Relative effects of oral and subcutaneous administration of cobaltous chloride | |
| OZAWA et al. | Sites of action of crystalline tetrodotoxin on sympathetic nervous systems | |
| CA1336491C (fr) | Composition pharmaceutique ayant une action antivirale | |
| Hoath et al. | Differential hormonal response of epidermal growth factor concentration in the developing mouse: Synergism of triiodothyronine and dexamethasone in epidermal maturation | |
| Stefko et al. | Experimental investigation of nine antitussive drugs | |
| AU598898B2 (en) | Methods for suppressing the endocrine system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |